Dr. Cascone on Combination Checkpoint Blockade for Early-Stage Non–Small-Cell Lung Cancer
Cancer Network spoke with Tina Cascone, MD, of MD Anderson Cancer Center, at ASCO 2019 about combination checkpoint blockade in the pre-surgical setting for early-stage NSCLC.
Cancer Network spoke with Tina Cascone, MD, an oncologist and assistant professor of Thoracic/Head & Neck Medical Oncology at MD Anderson Cancer Center, about the combination checkpoint blockade effective in the pre-surgical setting for early-stage non–small-cell lung cancer. The results of the study (abstract 8504) were presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
